Immuno-Biological Laboratories Co (4570.T) Stock Price
Immuno-Biological Laboratories Co Price
Immuno-Biological Laboratories Co (4570.T) Stock | ISIN JP3921300004. The current Immuno-Biological Laboratories Co stock price is 984 JPY (2026). Market capitalization is 9.16 B JPY. Immuno-Biological Laboratories Co operates in the Health sector.
Immuno-Biological Laboratories Co stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Immuno-Biological Laboratories Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Immuno-Biological Laboratories Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Immuno-Biological Laboratories Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Immuno-Biological Laboratories Co Price |
|---|
Immuno-Biological Laboratories Co Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Immuno-Biological Laboratories Co Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M JPY) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M JPY) |
| NET INCOME (M JPY) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Immuno-Biological Laboratories Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Immuno-Biological Laboratories Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Immuno-Biological Laboratories Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Immuno-Biological Laboratories Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Immuno-Biological Laboratories Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Immuno-Biological Laboratories Co stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Immuno-Biological Laboratories Co Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Immuno-Biological Laboratories Co business model & stock analysis
Immuno-Biological Laboratories Co Eulerpool Fair Value
Immuno-Biological Laboratories Co historical P/E ratio, EBIT multiple, and P/S ratio
Immuno-Biological Laboratories Co annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Immuno-Biological Laboratories Co shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Immuno-Biological Laboratories Co Dividend History
2 years of dividend payments
Immuno-Biological Laboratories Co dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Immuno-Biological Laboratories Co shareholder structure
| % | Name |
|---|---|
12.06982% | |
2.81305% | |
2.52417% | |
2.20193% | |
1.0913% | |
1.07411% | |
0.55854% | |
0.53706% |
Immuno-Biological Laboratories Co Executives and Management Board
Mr. Tsutomu Seito
(68)President, Representative Director · since 2021
Mr. Masato Nakagawa
(60)Managing Director, Chief Director of Business Group Administration · since 2008
Ms. Shoko Onodera
(61)Director of Human Resources and General Affairs, Manager of Internal Audit Office, President of Subsidiary, Director · since 2008
Mr. Daisuke Kawase
Executive Officer
Mr. Tatsuya Segawa
Executive Officer
Frequently asked questions about Immuno-Biological Laboratories Co
Immuno-Biological Laboratories Co stock
Immuno-Biological Laboratories Co Peer Group
Immuno-Biological Laboratories Co FIGI
All fundamentals and in-depth analysis of Immuno-Biological Laboratories Co
Our stock analysis for Immuno-Biological Laboratories Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuno-Biological Laboratories Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.